水飛薊 Milk Thistle × 肝硬化
When evidence is judged on clinically meaningful endpoints (mortality, decompensation, complications, histologic fibrosis) the totality is negative.
When evidence is judged on clinically meaningful endpoints (mortality, decompensation, complications, histologic fibrosis) the totality is negative. The authoritative 2005 Cochrane review (Rambaldi, 13 RCTs, n=915) found no significant effect on all-cause mortality (RR 0.78, 95% CI 0.53-1.15); the apparent liver-related mortality benefit (RR 0.50) vanished once analysis was restricted to high-quality trials (RR 0.57, 95% CI 0.28-1.19) - a classic small-study/low-quality-trial bias signal - with no effect on complications or histology. The single positive survival trial (Ferenci 1989, 58% vs 39%) is low quality and was not replicated by the larger 1998 multicenter alcoholic-cirrhosis trial, which found no benefit. EASL explicitly states silymarin showed no consistent beneficial effect on patient outcome in alcoholic cirrhosis; AASLD declines to recommend it; Mayo says it 'hasn't proved effective'; NCCIH calls liver-disease evidence conflicting/insufficient and notes two NIH-funded trials showed no benefit. Examine's grade B rests entirely on a 'Liver Enzymes' (ALT/AST) surrogate showing only a small improvement - a surrogate biomarker that the 2017 meta-analysis itself judged clinically irrelevant - and overstates real-world benefit. Graded D: the highest-quality evidence shows negligible-to-no effect on outcomes that matter to patients with cirrhosis.
評分透明度
所有分數由 7 層證據引擎計算，過程公開可查▸查看完整決策路徑（audit trail）
- compute_raw_score — 加權公式: L2×0.30 + L3×0.25 + L5×0.25 + L11×0.10 + L1×0.10 = 0.422
- tier_from_score — 依分數區間映射至 tier letter
- apply_hec_rules — 無高階證據可裁決
- tier_strict_requirement_check — Tier 條件達標，未降階
- detect_disputes — 偵測到 0 個 hard + 0 個 soft dispute
- decide_status — 依 tier + dispute 結果決定 status
台灣社群多把水飛薊當泛用「保肝」保健品討論，少有直接針對肝硬化的經驗；分享多為肝指數(GPT/GOT)下降心得，但鄉民普遍認為飲食運動作息才是主因。
分歧（多數討論為泛用保肝、肝指數下降的個人心得；針對肝硬化本身的實測經驗極少，且鄉民多認為療效歸因於飲食運動而非水飛薊本身）
- 腸胃不適（社群少提，多引自衛教，非肝硬化情境的具體鄉民回報）
- 頭痛（同上，提及度低）
依論壇被提及頻率，非銷售或品質排序。
- 藥局處方水飛薊膠囊（鄉民提一顆約 4 元、一天一顆）
- 卡幸B+（含水飛薊＋豬肝萃取物之複方）
- iHerb 進口水飛薊（如 Now Foods 等海外品牌，e-shopping 板常見）
- 斯斯保肝（留言提及之市售保肝品，非水飛薊單方）
⚠️ 列出僅代表「TW 社群討論度高」，不代表本站推薦或背書。本站不販售任何產品、無導購連結。
- 戒酒
- 限鈉飲食與利尿劑治療腹水
- 治療潛在病因（抗病毒治療、代謝管理）
查看 ClaimReview 結構化資料 (JSON-LD)
{
"@context": "https://schema.org",
"@type": "ClaimReview",
"url": "https://gpt-dict.com/claim/CLM-COND-liver-cirrhosis-INT-milk-thistle-001/",
"datePublished": "2026-06-01",
"author": {
"@type": "Organization",
"name": "gpt-dict.com",
"url": "https://gpt-dict.com"
},
"claimReviewed": "水飛薊能改善肝硬化",
"inLanguage": "zh-TW",
"itemReviewed": {
"@type": "Claim",
"appearance": []
},
"reviewRating": {
"@type": "Rating",
"ratingValue": 2,
"bestRating": 5,
"worstRating": 1,
"alternateName": "🟠 C 薄弱證據"
}
}